ライフサイエンスコーパス: glaucoma

1 , and was less likely to recommend MC use in glaucoma.

2 ure was the presence or absence of secondary glaucoma.

3 ntioned above and presentation with advanced glaucoma.

4 erform glaucoma surgery to treat progressive glaucoma.

5 ment to restore TM structure and function in glaucoma.

6 y 2.6% had used marijuana as a treatment for glaucoma.

7 = .02) as predictors for the development of glaucoma.

8 parameters in pathologic conditions such as glaucoma.

9 ct of SS on reliability is greater in severe glaucoma.

10 target for investigation in PEX syndrome and glaucoma.

11 early postoperative period in patients with glaucoma.

12 neuropathies, and ocular disorders, such as glaucoma.

13 tensity is associated with decreased odds of glaucoma.

14 l, 1.08-1.34) compared with patients without glaucoma.

15 poorer prognosis phenotype of neonatal-onset glaucoma.

16 t choices for those presenting with advanced glaucoma.

17 en with congenital aniridia with early-onset glaucoma.

18 ty to portray functional change over time in glaucoma.

19 n patients with ocular hypertension (OHT) or glaucoma.

20 diagnosed primary open-angle and exfoliation glaucoma.

21 ation in perturbing metabolism and promoting glaucoma.

22 ness remains the most efficient for advanced glaucoma.

23 y decrease success of angle surgery in other glaucoma.

24 the way clinicians manage data when managing glaucoma.

25 nt types of primary and secondary open angle glaucoma.

26 and how this use compares with those without glaucoma.

27 athway is activated in TM of human and mouse glaucoma.

28 ic tissue dysfunction and is associated with glaucoma.

29 eterioration is crucial for individuals with glaucoma.

30 rimary glaucoma and 74 (87.1%) had secondary glaucoma.

31 are at increased risk for the development of glaucoma.

32 c photographs for characteristic features of glaucoma.

33 l for a novel therapeutic target in treating glaucoma.

34 atch graft in pediatric and adult refractory glaucomas.

35 05) compared with eyes with mild or moderate glaucoma (-0.67 to -0.75 per 1-point decrease in SS; P <

36 er impact on reliability in eyes with severe glaucoma (-1.25 per 1-point decrease in SS; P < 0.05) co

37 pseudophakic, with mild/moderate open-angle glaucoma, 12-month follow-up, and medicated intraocular

38 h criteria), and younger age at diagnosis of glaucoma (18-39 years) was predictive of surgical succes

39 ne material was pro-MC use in the setting of glaucoma (24% of Google, 59% of YouTube, and 21% of Face

40 eted a fellowship, with the most frequent in glaucoma (24%), cornea and external diseases (22%), and

41 007), but not GFCS (36%) and other secondary glaucoma (29%).

42 The main indication was congenital glaucoma (29.4%).

43 y focal ischemic (41.8% [40.0-43.6]), myopic glaucoma (42.1% [40-44.2]), and generalized cup enlargem

44 on more frequently than participants without glaucoma (8.2% vs. 6.4% P = 0.024).

45 The first cohort included eyes with mild glaucoma (abnormal glaucoma hemifield test results, patt

46 s more frequent in South Asian patients, and glaucoma after cataract surgery more frequent in white p

47 The accuracy of the model in detecting glaucoma after onset was 0.95 (95% CI, 0.94-0.96).

48 my and ocular pathologic features, including glaucoma, age-related macular degeneration, and epiretin

49 spectively, after adjusting for age, gender, glaucoma, age-related macular degeneration, diabetic ret

50 One eye each of 39 glaucoma and 31 age-matched normal participants was scan

51 11 (12.9%) had primary glaucoma and 74 (87.1%) had secondary glaucoma.

52 (G) group (70 eyes/patients) diagnosed with glaucoma and a 24-2 mean deviation better than -6 dB and

53 and reverses vision loss in a mouse model of glaucoma and in aged mice.

54 ial neuroprotective effects of senolytics on glaucoma and other neurodegenerative diseases.

55 ological role of ATF4-CHOP-GADD34 pathway in glaucoma and provide a possible treatment for glaucoma b

56 electronic medical records of patients with glaucoma and suspected disease followed over time at the

57 A majority (80%) of children had bilateral glaucoma and underwent filtering surgery (83%).

58 es within the preceding 6 months, history of glaucoma, and corneal abnormalities affecting IOP measur

59 d functional tests should be used to monitor glaucoma, and spectral-domain OCT still has a relevant r

60 a other than pseudoexfoliative or pigmentary glaucoma, angle closure, previous incisional glaucoma su

61 ucoma-related procedures with or without non-glaucoma anterior segment surgery at the time of implant

62 for global RNFL thickness using the standard glaucoma application.

63 rneal ulceration and scarring, cataract, and glaucoma are factors associated with poor visual acuity.

64 with PCG more frequent in nonwhite patients, glaucoma associated with acquired conditions more freque

65 (nonsurgical group) for age, gender, type of glaucoma, baseline IOP, and number and type of glaucoma

66 For the diagnosis of early glaucoma, both macular and optic disc scans should be us

67 vals of Rhopressa, Vyzulta, and Roclatan for glaucoma, Brolucizumab for wet age-related macular degen

68 eard about the possible use of marijuana for glaucoma, but only 2.6% had used marijuana as a treatmen

69 laucoma and provide a possible treatment for glaucoma by targeting this pathway.

70 Risk factors for visual field progression in glaucoma can affect both eyes, meaning that progression

71 sonalized education to be a standard part of glaucoma care.

72 e angle structure and the pathophysiology of glaucoma caused by MPS.

73 , (2) 3 in-person counseling sessions with a glaucoma coach who had training in motivational intervie

74 strated substantial overlap with healthy and glaucoma cohorts.

75 Blacks or Asians, comorbid glaucoma, concurrent or prior glaucoma surgery, and lowe

76 The diagnoses of neovascular glaucoma, CRVO and CRAO were established as affirmed wit

77 n a map, which we refer to as an "AI-enabled glaucoma dashboard." We used density-based clustering an

78 tively small proportion of the patients with glaucoma demonstrated visual impairment.

79 urements can improve diagnostic accuracy for glaucoma detection compared to most but not all instrume

80 Glaucoma developed in 31 eyes (16%) with 5- and 10-year

81 he topics of cataract, macular degeneration, glaucoma, diabetic retinopathy, and near-sightedness usi

82 ewed 566 patients with primary and secondary glaucoma diagnoses who received trabeculectomy surgery w

83 sians (HR: 1.26; 95% CI: 1.10-1.45) having a glaucoma diagnosis (HR: 1.53; 95% CI: 1.46-1.60), prior

84 Beginning at an initial glaucoma diagnosis at age 40 years, patients proceeded t

85 ld be aware that the performance of OCTA for glaucoma diagnosis may be influenced by the optic disc p

86 Glaucoma disproportionately affects individuals of Afric

87 ion, trabeculectomy with anti-fibrotics, and glaucoma drainage device placement were assessed.

88 with DSAEK failure in patients with previous glaucoma drainage device surgery.

89 eculectomy with anti-fibrotics and Baerveldt glaucoma drainage devices showed the greatest success in

90 Glaucoma drainage implant-associated endophthalmitis was

91 ate the risk of dry eye syndrome, cataracts, glaucoma, episcleritis and scleritis, and retinal vascul

92 creased risk of dry eye syndrome, cataracts, glaucoma, episcleritis and scleritis, and retinal vascul

93 TBK1-associated glaucoma exhibits classic features of NTG.

94 image and parafoveal deep macular vessels in glaucoma eyes (21.0%+/-8.7%, 24.4%+/-9.6%) were signific

95 ison of the "hit rate," or the proportion of glaucoma eyes categorized as progressing at each time po

96 Pseudoexfoliation glaucoma eyes demonstrate reduced LC and PLT thickness c

97 detection of change on macular OCT images in glaucoma eyes.

98 A glaucoma (G) group (70 eyes/patients) diagnosed with gla

99 y located at the centre of the cornea in the glaucoma group (P = 0.039).

100 F-BUA was higher in the glaucoma group than in the control group (2.73 and 2.28;

101 in the open-angle and 74 in the exfoliation glaucoma group.

102 Patients with glaucoma had significantly slower saccades (602.9 +/- 50

103 eiving an implant on implantation) developed glaucoma (hazard ratio [HR] = 5.9, 95% confidence interv

104 duction for patients with primary open-angle glaucoma (hazard ratio [HR], 1.19; 95% confidence interv

105 mean deviation, pattern standard deviation, glaucoma hemifield test results, FPR, FNR, and FL); (2)

106 t included eyes with mild glaucoma (abnormal glaucoma hemifield test results, pattern standard deviat

107 and management of IOL decentrations, uveitis-glaucoma-hyphema (UGH) syndrome, IOL opacifications, and

108 tment with a tube shunt (350-mm(2) Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (MM

109 cell types that express genes implicated in glaucoma in all five species.

110 n may improve the detection and diagnosis of glaucoma in Asians.

111 Sixty-four patients (39.8%) showed advanced glaucoma in at least 1 eye at presentation.

112 sequencing and metabolomics to examine early glaucoma in DBA/2J mice.

113 howed good diagnostic accuracy for detecting glaucoma in ED patients, their diagnostic accuracy was o

114 t sensitivity and specificity in identifying glaucoma in myopic eyes.

115 as a complementary test in the diagnosis of glaucoma in myopic preperimetric eyes.

116 participants with a diagnosis of open angle glaucoma in one or both eyes and a visual acuity of 20/4

117 incidence of primary and secondary childhood glaucoma in Scotland over a 2-year period.

118 oma with concomitant seeding and neovascular glaucoma in the right eye was seen for a second opinion

119 ciated with use of LT as primary therapy for glaucoma, including factors related to patient demograph

120 ificant difference within different types of glaucoma, including open-angle glaucoma (P = 0.36), chro

121 The cumulative incidence of glaucoma-induced visual impairment in at least 1 eye inc

122 diseases caused by various insults including glaucoma, inflammation, ischemia, trauma, and genetic de

123 PEX glaucoma is a common, aggressive form of open-angle glau

124 Glaucoma is a group of progressive optic neuropathies th

125 canalization in different forms of pediatric glaucoma is under-reported.

126 ent survey assessed demographics, history of glaucoma, knowledge and rate of marijuana use, and perce

127 or OHT that underwent MPCPC (Iridex Cyclo G6 Glaucoma Laser System, Mountain View, CA) between 2016 a

128 Glaucoma-like neuropathies can be experimentally induced

129 .6-6.2]; P < 0.001) and moderate to advanced glaucoma (mean, 34.7% and 38.5%, respectively; adjusted

130 und in ED eyes compared with AD eyes in mild glaucoma (mean, 42.2% [95% confidence interval (CI), 41.

131 he impact of the iStent on the comprehensive glaucoma Medicare expenditure in the same time period wa

132 f-administered their eye drops, and had poor glaucoma medication adherence (defined as taking <=80% o

133 pleted a survey on demographics, barriers to glaucoma medication adherence, and self-adherence (measu

134 ost-utility value of adherence to prescribed glaucoma medication are vital to implement potentially e

135 measures were survival rate for IOP control, glaucoma medication use, complication rate, and vision.

136 on who were aged >=40 years, were taking >=1 glaucoma medication, spoke English, self-administered th

137 laucoma patients aged >=40 years, taking >=1 glaucoma medication, who self-reported poor adherence) c

138 1), but there was no difference in number of glaucoma medications (1.6 +/- 1.5, p = 0.1).

139 s (P = .357), mean IOP (P = .707), number of glaucoma medications (P = 1.000), bleb height (P = .625)

140 clinical hypotony without (complete) or with glaucoma medications (qualified); and (2) at least a 20%

141 reduction <20% from baseline, or increase in glaucoma medications from baseline.

142 defined as IOP >21 mmHg on maximum tolerated glaucoma medications or progressive visual field and opt

143 up at 3 years (P = 0.008), and the number of glaucoma medications was 2.1+/-1.4 in the tube group and

144 Median number of preoperative glaucoma medications was 2.5 (range 0-5, mean 2.6); medi

145 ed visual acuity (BCVA) logMAR and number of glaucoma medications were recorded prior to the study, a

146 ncluding age, preoperative IOP, preoperative glaucoma medications, and previous glaucoma surgeries.

147 ified success) or without (complete success) glaucoma medications.

148 ed distress all predicted lower adherence to glaucoma medications.

149 = 29, P = 0.519) on 2.0 +/- 1.6 (P = 0.457) glaucoma medications.

150 aucoma, baseline IOP, and number and type of glaucoma medications.

151 ted visual acuity, intraocular pressure, and glaucoma medications/surgeries.

152 Hence, this infusion-based glaucoma model exhibits graded neural damage with unimpa

153 reduction of intraocular pressure in murine glaucoma models.

154 Among the 231 respondents with glaucoma, most (58.9%) had heard about the possible use

155 ma surgery (ST), eyes with medically treated glaucoma (MT), and eyes without glaucoma (NG).

156 generalized cup enlargement (n = 60), myopic glaucoma (n = 38), and senile sclerotic (n = 50).

157 those with neonatal-onset primary congenital glaucoma (N-PCG).

158 29.2 +/- 6.5, and 8.6 +/- 1.4 for cataract, glaucoma, near-sightedness, diabetic retinopathy, and ma

159 ally treated glaucoma (MT), and eyes without glaucoma (NG).

160 rio is distinguishing between normal tension glaucoma (NTG) and non-glaucomatous optic neuropathies (

161 ) on iStent inject(R) outcomes in open-angle glaucoma (OAG).

162 intraocular pressure (IOP) in patients with glaucoma, ocular hypertension, anatomic narrow angles, a

163 iFU in patients with uncontrolled open-angle glaucoma on maximum tolerated medical therapy.

164 r at surgery conferred an increased risk for glaucoma or glaucoma suspect designation (younger age: o

165 In this study, 147 eyes from 96 glaucoma or glaucoma suspect patients were followed for

166 Eyes with glaucoma or glaucoma suspect were excluded from the prim

167 ine patients with a diagnosis of any kind of glaucoma or ocular hypertension who were aged >=40 years

168 Consecutive eyes with glaucoma or OHT that underwent MPCPC (Iridex Cyclo G6 Gl

169 -five right eyes of 95 patients followed for glaucoma or OHT were included.

170 ing versus sitting had 58% decreased odds of glaucoma (OR, 0.42; 95% CI, 0.25-0.70).

171 1;P = 0.02), higher prevalence of open-angle glaucoma (OR, 2.40; 95% CI, 1.36-4.23;P = 0.003), and hi

172 ic anhydrase have a positive effect, such as glaucoma, or act as diuretics.

173 line, IOP of 5 mmHg or less, reoperation for glaucoma, or loss of light perception vision.

174 Eyes with secondary glaucoma other than pseudoexfoliative or pigmentary glau

175 rent types of glaucoma, including open-angle glaucoma (P = 0.36), chronic angle closure glaucoma (P =

176 e glaucoma (P = 0.36), chronic angle closure glaucoma (P = 0.85) and OHT (P = 0.42).

177 on of both childhood and juvenile open-angle glaucoma, particularly when associated with iris abnorma

178 is of ADRVD may improve our understanding on glaucoma pathogenesis, offering new treatment insights.

179 loss based on longitudinal data from a real glaucoma patient (thereby controlling for other variable

180 Third, the self-administered glaucoma patient survey assessed demographics, history o

181 Glaucoma patients >= age 40, taking >=1 medication, who

182 One eye each of 97 glaucoma patients (median mean deviation, -2.31 dB) and

183 tous visual field damage compared to matched glaucoma patients (n = 26) without senolytic exposure.

184 Participants (University of Michigan glaucoma patients aged >=40 years, taking >=1 glaucoma m

185 At worse levels of VF damage, glaucoma patients demonstrate shorter, more fragmented b

186 Open-angle glaucoma patients may have increased odds of SD, MCI, an

187 New-diagnosed exfoliation glaucoma patients must be controlled and treated more st

188 reated more strictly than primary open-angle glaucoma patients to avoid visual field deterioration.

189 In this study of glaucoma patients with early damage with the 24-2 test,

190 OCT to distinguish between healthy and mild glaucoma patients, comparing those readings with the sta

191 better VF and VRQoL than secondary childhood glaucoma patients.

192 by enlarging the functional field of view in glaucoma patients.

193 promises to revolutionize the management of glaucoma patients.

194 Primary congenital glaucoma (PCG) was the most common diagnosis (45.4%, n =

195 Four glaucoma phenotypes were assessed: focal ischemic (n = 4

196 ssociation between age, type and severity of glaucoma, pigmentation of the trabecular meshwork (PTM),

197 -sectional study: 68 mild primary open-angle glaucoma (POAG) patients according to the Hodapp-Parrish

198 ) sensor in patients with primary open angle glaucoma (POAG).

199 Failure of SLT was defined as any further glaucoma procedure post-SLT or any of the following at 2

200 ffer an outcome metric to which future novel glaucoma procedures in children can be compared.

201 bout experience and confidence in a range of glaucoma procedures, number of patients requiring referr

202 data improves the model's ability to assess glaucoma progression and better reflects the way clinici

203 is to review the challenges to detection of glaucoma progression with macular OCT imaging and propos

204 synergistically with CCT as risk factors for glaucoma progression.

205 h fluctuations or peaks likely contribute to glaucoma progression.

206 tem in pseudophakic patients with open-angle glaucoma provides effective IOP reduction or sustained I

207 Age, type and severity of glaucoma, PTM, or total energy delivery had no associati

208 Data were extracted from the Duke Glaucoma Registry, a large database of electronic medica

209 Glaucoma-related distress (mean score 5.6, SD = 3.0) was

210 ducational attainment, and a higher level of glaucoma-related distress all predicted lower adherence

211 4) consideration of future consequences; (5) glaucoma-related distress; and (6) social support.

212 (<1 year; HR, 27; P = 0.0053) and concurrent glaucoma-related procedures with or without non-glaucoma

213 stoperative follow-up >180 days and no other glaucoma-related surgery within the prior year.

214 ity of our atlas was demonstrated by mapping glaucoma-relevant genes to outflow cell clusters.

215 Participants with glaucoma reported they could not afford prescribed medic

216 orrhage, retinal detachment, and neovascular glaucoma, respectively).

217 a is a common, aggressive form of open-angle glaucoma resulting from the deposition of fibrillary mat

218 In blinding disorders such as glaucoma, RGCs are the main cell type to degenerate and

219 howed elevated IOP and at least 1 additional glaucoma risk factor (i.e., they were high-risk patients

220 Patients with pediatric glaucomas seen at the University of Minnesota over 8.5 y

221 Additional glaucoma self-management support resources should be dir

222 rate was associated significantly with worse glaucoma severity (P = 0.037).

223 he association between GCC thinning rate and glaucoma severity was not significant (P = 0.586).

224 djusting for potential confounders including glaucoma severity, CS, age, and visual acuity (P = .004

225 Age, glaucoma severity, total SLT power, type of glaucoma, se

226 glaucoma severity, total SLT power, type of glaucoma, severity of glaucoma, visual field mean defect

227 ders prescribing medication to patients with glaucoma should be aware of these findings and consider

228 People with glaucoma showed lower scores on cognitive tests that may

229 Here, small-lumen, nano-structured glaucoma shunts were manufactured with or without a degr

230 ular pathology such as macular degeneration, glaucoma, Sicca syndrome, epiretinal membrane, cornea gu

231 rsement from surgical cancellations of the 4 glaucoma specialists was $208 306.

232 a Markov model with Hodapp-Parrish-Anderson glaucoma stages (mild, moderate, advanced, severe or bli

233 -MD and VF-MD in early, moderate, and severe glaucoma stages were -0.9 +/- 2.0, 0.9 +/- 2.9, and 5.8

234 to groups matched for baseline demographics, glaucoma status, and baseline IOP.

235 Throughout the study period, glaucoma subspecialists performed most of the trabeculec

236 ing information from MAC and ONH in advanced glaucoma, suggesting that structural changes of the 2 re

237 Micro- or minimally invasive glaucoma surgeries (MIGS) have been the latest addition

238 y is to compare the effectiveness of various glaucoma surgeries on intraocular pressure (IOP) managem

239 operative glaucoma medications, and previous glaucoma surgeries.

240 t surgery (aHR, 0.70; 95% CI 0.56-0.88), and glaucoma surgery (aHR, 0.63; 95% CI, 0.45-0.90).

241 agnosis (HR: 1.53; 95% CI: 1.46-1.60), prior glaucoma surgery (HR: 1.26; 95% CI: 1.18-1.35), and conc

242 HR: 1.26; 95% CI: 1.18-1.35), and concurrent glaucoma surgery (HR: 1.31; 95% CI: 1.20-1.44).

243 were divided into 3 groups: eyes with prior glaucoma surgery (ST), eyes with medically treated glauc

244 , and 13.8% of all eyes in this study needed glaucoma surgery at 1-, 5-, and 8-years of follow-up, re

245 Ophthalmologists commonly perform glaucoma surgery to treat progressive glaucoma.

246 The cumulative probability of incisional glaucoma surgery was lower in the microstent group (0.6%

247 Thirty-one eyes of 18 patients required glaucoma surgery with 2.2 +/- 1.2 IOP-lowering surgeries

248 lysis of 1582 eyes that underwent incisional glaucoma surgery yielded a 5-year cumulative incidence f

249 athy, giant retinal tears, previous invasive glaucoma surgery, and <=90 days of follow-up were exclud

250 th proliferative vitreoretinopathy, previous glaucoma surgery, and giant retinal tears were excluded,

251 ians, comorbid glaucoma, concurrent or prior glaucoma surgery, and lower volumes of surgery are assoc

252 egeneration, diabetic retinopathy, cataract, glaucoma surgery, cataract surgery, and first-order inte

253 sequent operative intervention or additional glaucoma surgery, or a catastrophic event such as loss o

254 glaucoma, angle closure, previous incisional glaucoma surgery, or any significant ocular pathology ot

255 to monitor across time intervals containing glaucoma surgery.

256 additional consideration should be given to glaucoma surgical planning in patients receiving anti-VE

257 (MIGS) have been the latest addition to the glaucoma surgical treatment paradigm.

258 conferred an increased risk for glaucoma or glaucoma suspect designation (younger age: odds ratio [O

259 Glaucoma suspect eyes with higher corneal SPs and lower

260 isualize the data in 2-dimensional clusters, glaucoma suspect patients demonstrated substantial overl

261 In this study, 147 eyes from 96 glaucoma or glaucoma suspect patients were followed for a mean of 3.

262 Eyes with glaucoma or glaucoma suspect were excluded from the primary analysis

263 entify pre-perimetric glaucomatous damage in glaucoma suspects than BMO-MRW.

264 hypertension, anatomic narrow angles, and in glaucoma suspects, but the magnitude of change has varie

265 The implant has substantially higher risk of glaucoma than systemic therapy, a difference not entirel

266 ganglion cell degeneration is a hallmark of glaucoma, the leading cause of irreversible blindness.

267 particularly in eyes with primary open angle glaucoma, the number of cells residing within the TM is

268 Here we modeled neurodegeneration in glaucoma, the world's leading cause of irreversible blin

269 the 4-year period suggest an unmet need for glaucoma therapies with durable and predictable actions.

270 exposing a potential pathway for alternative glaucoma therapies.

271 conflicting opinions on marijuana's role in glaucoma therapy.

272 nerve head and may provide a new avenue for glaucoma therapy.

273 In a neuroinflammatory model of glaucoma, TNF-alpha induces SARM1-dependent axon degener

274 Patients with glaucoma treated from June 2010 through May 2015 who und

275 Open-angle glaucoma treatment costs and effects were projected over

276 on the basis of data from the United Kingdom Glaucoma Treatment Study.

277 BS-Cat: 23.81%; BT-Cat: 20.00%; P = .67) and glaucoma (US-Cat: 6.76%; BS-Cat: 15.87%; BT-Cat: 15.00%;

278 at proportion of United States patients with glaucoma use eHealth and how this use compares with thos

279 ns with IOP using linear regression and with glaucoma using logistic regression.

280 The 5-fold cross-validated AUC for glaucoma versus nonglaucoma from logistic regression mod

281 tal SLT power, type of glaucoma, severity of glaucoma, visual field mean defect, and retinal nerve fi

282 ments alone, the median indemnity payment in glaucoma was $955 988, compared with $827 051 for all op

283 For jury verdicts alone, the median award in glaucoma was $977 474, compared with $604 352 for all op

284 Glaucoma was defined according to the International Soci

285 Refractory glaucoma was defined as IOP >21 mmHg on maximum tolerate

286 Advanced glaucoma was defined by a cup-to-disc ratio of 0.85 or h

287 Glaucoma was defined with 2 definitions based on (1) the

288 The relationship between caffeine intake and glaucoma was null (P >= 0.1).

289 ve inhibitors against isoforms implicated in glaucoma were assessed in a rabbit model of the disease

290 ession to advanced AMD, whereas diabetes and glaucoma were associated with a decreased rate of progre

291 any significant ocular pathology other than glaucoma were excluded.

292 n 71 years) with an established diagnosis of glaucoma were issued a tablet perimeter (Eyecatcher) and

293 Rejection and diagnosis of congenital glaucoma were risk factors for graft failure.

294 hickness for the diagnosis of early/moderate glaucoma, whereas cpRNFL thickness remains the most effi

295 ective and subjective exercise intensity and glaucoma while controlling for all covariates.

296 participants with and without self-reported glaucoma who reported cost-related nonadherence over the

297 Fifty-nine patients with glaucoma who were using at least 3 or more eye drops wer

298 tal of 29 patients with history of childhood glaucoma, who were treated unilaterally with PGAs for at

299 popularity continues to grow, patients with glaucoma will encounter conflicting opinions on marijuan

300 nts with ocular hypertension and exfoliation glaucoma (XFG).